Last mentioned: Mar 7, 2026
Final Departure
Official announcement of Marks leaving the agency for the second time.
Formal Proposal
FDA formally proposes the new customized drug approval system for ultra-rare diseases.
BGTC Pilot Completion
The Bespoke Gene Therapy Consortium completes its first round of pilot manufacturing runs.
Initial Friction
Reports surface of Marks considering resignation amid administrative policy shifts.
Draft Guidance Issued
FDA releases initial thoughts on 'n-of-1' therapy development and manufacturing.
PREVENT Act Passed
Congress directs FDA to establish a framework for platform technology designations.
Operation Warp Speed
Plays a central role in the emergency use authorizations for COVID-19 vaccines.
Appointed Director
Promoted to Director of CBER, overseeing the 'Gold Standard' of vaccine review.
Joins FDA
Dr. Peter Marks joins the FDA as Deputy Director of CBER.
Dr. Peter Marks, the long-serving head of the FDA’s vaccine division, is stepping down for the second time as the Trump administration intensifies its 'Make America Healthy Again' initiatives. His exit marks a critical turning point for the Center for Biologics Evaluation and Research and signals a potential shift in the agency's rigorous approval standards.
The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.